GSK reported strong Q3 2025 results with sales of £8,547 million, up 8% year-over-year, and upgraded its full-year 2025 guidance1.
Emma Walmsley, CEO, led what is understood to be her final earnings presentation, highlighting a continued focus on core growth drivers and portfolio quality13.
Specialty Medicines sales drove performance, increasing by 16%, particularly led by RI&I (Respiratory, Inflammation and Immunology), Oncology, and HIV franchises1.
The company advanced its R&D portfolio, noting 4 FDA approvals in 2025 and progress toward launching 15 scale opportunities between 2025 and 20311.
GSK reported core operating profit of £2,985 million, up 11%, and core EPS of 55.0p, up 14% from the prior year1.
Strong cash generation was highlighted, with £6.3 billion generated from operations year-to-date, supporting investment and shareholder returns1.
GSK continued to invest in innovative early-stage pipeline assets, while also consolidating and trimming less promising candidates from its development portfolio to focus resources on higher-potential opportunities1.
A 16p dividend per share was declared, and the company maintained a high performance against responsible business metrics1.
This quarter marks Emma Walmsley’s last as CEO, closing her tenure with improved financials and renewed strategic focus13.
Sources:
1. https://www.gsk.com/media/0qfjbtd3/q3-2025-results-slides.pdf